Neoadjuvant therapy for gastric cancer: current evidence and future directions

Andrew D. Newton¹, Jashodeep Datta¹, Arturo Loaiza-Bonilla², Giorgos C. Karakousis¹, Robert E. Roses¹

¹Department of Surgery, ²Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

Correspondence to: Robert E. Roses, MD. Department of Surgery, University of Pennsylvania Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA. Email: robert.roses@uphs.upenn.edu.

Abstract: Although surgical resection remains the only potentially curative treatment for gastric cancer (GC), poor long-term outcomes with resection alone compel a multimodality approach to this disease. Multimodality strategies vary widely; while adjuvant approaches are typically favored in Asia and the United States (USA), a growing body of evidence supports neoadjuvant and/or perioperative strategies in locally advanced tumors. Neoadjuvant approaches are particularly attractive given the morbidity associated with surgical management of GC and the substantial risk of omission of adjuvant therapy. The specific advantages of chemoradiotherapy (CRT) compared to chemotherapy have not been well defined, particularly in the preoperative setting and trials aimed at determining the optimal elements and sequencing of therapy are underway. Future studies will also define the role of targeted and biologic therapies.

Keywords: Gastric cancer (GC); neoadjuvant therapy; multimodality therapy; surgery; chemotherapy; radiotherapy; chemoradiotherapy (CRT)

Submitted Feb 21, 2015. Accepted for publication Mar 10, 2015.
View this article at: http://dx.doi.org/10.3978/j.issn.2078-6891.2015.047

Introduction

In 2012, there were an estimated 951,000 new diagnoses of gastric cancer (GC) and 723,000 GC deaths worldwide, accounting for 6.8% of all cancer diagnoses and 8.8% of all cancer related deaths (1). In the United States (USA) in 2014, an estimated 22,220 new diagnoses and 10,990 deaths were attributable to GC (2). GC is more prevalent in Eastern Asian countries; China accounts for the largest number of cases. In certain countries (e.g., Japan), established GC screening programs enable cancer detection at earlier stages; consequently, 5-year survival for affected patients in Japan is nearly 52%, comparing favorably to survival rates in other parts of the world. Notably, 5-year survival in the USA, Europe, and China remain poor at 20-25% (3).

Surgical resection is the only potentially curative treatment for GC. Adjuvant and neoadjuvant perioperative approaches, including chemotherapy and/or radiotherapy are now increasingly used in conjunction with surgery for locally advanced disease and even early stage disease; however, little consensus exists regarding optimal treatment sequencing. Indeed, competing approaches are supported by randomized data of variable quality. Compared with surgery alone, a survival advantage has been demonstrated with adjuvant chemotherapy in Asian trials, adjuvant chemoradiotherapy (CRT) in the largest North American study, and perioperative chemotherapy in the most cited European trial. In this review, we summarize the existing strategies and future directions in multimodality therapy for GC treatment, with a particular focus on the emerging role of, and rationale for, neoadjuvant approaches.

Adjuvant therapy for GC

In Eastern Asia, adjuvant chemotherapy alone is the standard of care, with multiple trials demonstrating benefit for this approach. Sakuramoto et al. (i.e., ACTS-GC trial) demonstrated superior overall survival (OS) with surgery
followed by S-1 therapy compared with surgery alone. In this randomized controlled trial (RCT), 529 patients were randomized to D2 gastrectomy followed by S-1 beginning within 6 weeks of surgery and continuing for one year. Five hundred and thirty patients were randomized to D2 gastrectomy alone (4). At five years, disease-free survival (DFS) (65.4% vs. 53.1%) and OS (71.7% vs. 61.1%) were improved with adjuvant S-1 compared with surgery alone (5).

In a smaller Japanese study of 190 patients with T2N1 or N2 GC, OS was significantly improved (86% vs. 73%) with surgery followed by 16 months of oral uracil-tegafur compared to surgery alone (6). Results of the CLASSIC trial were similar, although outcomes were reported after only three years. In this study, 1,035 patients were randomized to D2 gastrectomy followed by eight 3-week cycles of adjuvant capecitabine and oxaliplatin (XELOX) or D2 gastrectomy alone. At three years, adjuvant XELOX significantly improved DFS (74% vs. 59%, P<0.0001) and OS (83% vs. 78%, P=0.0493) compared with surgery alone (7).

With the exception of one small trial in Spain (8), Western studies have failed to reproduce results from Asia demonstrating a survival benefit with adjuvant chemotherapy alone (9-20). Although a large meta-analysis of RCTs investigating the impact of postoperative chemotherapy versus surgery alone in GC reinforced the survival impact of adjuvant chemotherapy (21), these results were largely driven by Japanese trials.

The disparate outcomes with adjuvant chemotherapy in Eastern and Western studies may be explained by differences in the genetic underpinnings of the disease and/or surgical approach in the two regions. Data from the USA suggests that Japanese-Americans have superior stage-matched survival compared to all other Americans. Notably, GC in Japanese-Americans is characterized by fewer proximal tumors, a lower male to female ratio, and less frequent adjacent organ resection (22). A different biology hypothesis is further supported by results from the multinational Avastin in Gastric Cancer (AVAGAST) trial, which examined the addition of bevacizumab to first-line capecitabine and cisplatin (XP) chemotherapy in unresectable patients. While Asian patients benefited least from the addition of bevacizumab, their median OS in the XP chemotherapy-only arm was markedly longer than pan-American patients—12.1 vs. 6.8 months, respectively (23).

In addition, more standardized surgery with uniform D2 gastrectomy and increased extirpation of regional lymph nodes (LN) in Asia may account for reduction in residual tumor burden, and consequent lower rates of systemic failure following chemotherapy. We recently demonstrated that, even in patients receiving adjuvant therapy in the USA, inadequate surgical LN staging (<15 nodes examined) was associated with worse risk-adjusted OS compared with adequate staging, supporting the notion that standardized surgery may translate to better outcomes and allow more rational selection of adjuvant therapy (24).

While support for adjuvant chemotherapy alone in North American and European patients is lacking, the USA Intergroup-0116 trial indicated improved DFS and OS with adjuvant CRT compared with surgery alone. Patients were randomized to surgery alone or adjuvant therapy with 5 weeks of fluorouracil and leucovorin followed by 5 weeks of radiotherapy with an additional 5-day fluorouracil cycle one and two months following completion of radiotherapy. Median OS was significantly longer in the CRT arm compared with surgery alone (36 vs. 27 months, P=0.005) (25). There was sustained improvement in DFS and OS at 10-year follow-up [hazard ratio (HR) for OS 1.32 (95% CI: 1.10-1.60; P=0.0046); HR for RFS 1.51 (95% CI: 1.25-1.83; P<0.001)] (26). However, this study has been criticized for lack of surgical standardization—only 10% of patients underwent D2 resections, whereas over 50% underwent D0 resection—which may have led to overestimation of the effect of CRT.

While the additional contribution of adjuvant radiotherapy to chemotherapy has not been examined in a randomized fashion in the USA or Europe, the 2013 Korean phase III ARTIST trial demonstrated no incremental survival benefit with the addition of radiotherapy to postoperative XP chemotherapy following D2 gastrectomy. Interestingly, subgroup analysis suggested improved DFS in patients with LN metastasis in the CRT arm compared to the chemotherapy alone arm (27). While these data lend further credence to the hypothesis that radiotherapy may have compensated for inadequate surgery in the Intergroup-0116 trial, the applicability of evidence from Asia—where standardized surgery is the norm—regarding dispensability of adjuvant radiotherapy to USA/European patients is uncertain.

Rationale for a neoadjuvant approach in gastrointestinal malignancies

There are numerous purported, and some proven, advantages of a neoadjuvant approach—particularly chemotherapy—in the treatment of aggressive solid tumor malignancies. Early treatment of distant microscopic disease, the ability
to gauge in vivo response to therapy, and the potential for
tumor downstaging to enhance resectability are frequently
invoked and may translate to better outcomes (28).
A neoadjuvant strategy may increase the likelihood of
completing multimodality therapy, particularly when surgical
management is associated with significant morbidity and
complications may preclude timely adjuvant therapy (29,30).

Application of radiotherapy in the neoadjuvant setting
has several additional and distinct advantages. The presence
of intact tumor and preserved normal anatomy facilitates
treatment planning and may limit toxicity to adjacent
organs. Conversely, adjuvant radiotherapy mandates higher
dosing and larger treatment fields with the potential for
increased toxicity. Such advantages have translated into
better outcomes in rectal and esophageal cancer. In rectal
cancer, preoperative CRT decreases locoregional recurrence
compared to postoperative CRT (31,32). Preoperative,
compared with postoperative, CRT also decreases the
incidence of grade 3 and 4 adverse events and long-term
toxic effects (31), and improves sphincter preservation (33,34).
In esophageal cancer, neoadjuvant CRT improves DFS
and OS compared with surgery alone (35). The success of
preoperative radiotherapy in esophageal and rectal cancer
may be related to the anatomic location of the esophagus
and rectum in enclosed spaces where the ability to achieve a
negative radial margin may be challenging and treatment can
be administered with less risk of toxicity to adjacent organs.

The perception that a neoadjuvant approach may
compromise curative therapy in a subset of patients that
progress prior to surgery is largely unfounded. Conversely,
identification of patients who can be spared a potentially
morbid non-curative resection (i.e., those that would recur
distantly at an early time point) is an additional advantage of
a neoadjuvant approach. There is a potential for treatment-
related toxicity that may preclude surgical therapy in
patients with curable disease. Notwithstanding, the poor
outcomes associated with surgery alone for all but early
stage gastrointestinal malignancies mitigate such concerns.

National, regional, institutional and disease site-specific
trends influence approach. Generally, a nuanced approach
whereby patients with clinical early stage disease are treated
with surgery first and those with locally advanced disease
receive neoadjuvant therapy is increasingly advocated.
The former group undergoes potentially curative surgery
without delay, and decisions regarding adjuvant therapy
are predicated on more accurate pathologic staging.
Neoadjuvant therapy is used to select a subset of patients
from the latter group for whom surgical resection is most
appropriate.

Many of the aforementioned advantages of neoadjuvant
therapy in general are applicable to the treatment of
GC. First, even with an R0 resection, local and systemic
recurrence is common (36), suggesting that early treatment
of occult microscopic disease could decrease recurrence.
Second, gastrectomy for GC is associated with substantial
morbidity (29). Neoadjuvant therapy may increase the
likelihood of multimodality therapy completion. Third, the
ability to gauge treatment response is relevant as treatment
response to neoadjuvant therapy predicts long-term
outcome (37); a favorable response may, therefore, justify an
aggressive surgical approach.

Neoadjuvant and perioperative chemotherapy in GC

One of the early RCTs investigating the impact of
neoadjuvant chemotherapy in GC was the Dutch FAMTX
trial. This trial included 59 patients—29 were randomized
to receive four cycles of 5-fluorouracil, leucovorin, and
methotrexate (FAMTX) followed by surgery, while 30 were
randomized to surgery alone. Neoadjuvant FAMTX did not
significantly improve survival compared to surgery alone
(30 vs. 18 months, P=0.17), although the trial was likely
underpowered (38).

The United Kingdom Medical Research Council
MAGIC trial was the first large RCT to demonstrate
a benefit for perioperative chemotherapy in GC and
gastroesophageal (GE) cancer. Five hundred three patients
with stage T2 or higher potentially resectable gastric
(74%), distal esophageal (11%), or esophagogastric junction
(EGJ) adenocarcinomas (15%) were randomly assigned to
surgery alone or surgery plus perioperative chemotherapy
with epirubicin, cisplatin, and fluorouracil (ECF). This
regimen consisted of three preoperative and three
postoperative cycles of intravenous epirubicin (50 mg/m²)
and cisplatin (60 mg/m²) on day 1, and a continuous intravenous
infusion of fluorouracil (200 mg/m²/day) for 21 days.
The primary end point was OS. Patients in the perioperative
chemotherapy group had similar rates of postoperative
complications and death within 30 days compared to those
in the surgery alone group. Although only 42% of patients
were able to complete protocol treatment, more patients
in the perioperative chemotherapy group were able to
undergo surgery (79% vs. 70%), and resected tumors were
significantly smaller (T1/T2 52% vs. 37%) with fewer
regional nodal metastases (N0/N1 84% vs. 71%) compared
to the surgery alone cohort. In addition, patients in the
perioperative chemotherapy group had improved OS compared with patients in the surgery only group (HR for death 0.75, 95% CI: 0.60-0.93; P=0.009; 5-year survival rate, 36% vs. 23%) as well as a progression-free survival benefit (HR 0.66; 95% CI: 0.53 to 0.81; P<0.001). The most notable ECF-related adverse effect was neutropenia (23%); however, less than 12% of patients experienced serious (grade 3 or 4) toxicity. Notably, nearly half of patients in the perioperative chemotherap group did not complete the adjuvant ECF component of their treatment plan, suggesting that this survival benefit was largely derived from neoadjuvant ECF (39).

A similar benefit was reported in the French FNLC/FFCD trial, where a similar population was randomized to receive 2-3 cycles of preoperative and 3-4 cycles of postoperative chemotherapy (infused fluorouracil 800 mg/m^2 daily for five days plus cisplatin 100 mg/m^2 on day 1 or 2, every four weeks) or surgery alone (113 vs. 111 patients, respectively). Higher rates of R0 resection (84% vs. 73%, P=0.04), improved 5-year DFS (34% vs. 19%, HR 0.65; 95% CI: 0.48-0.89, P=0.003), and improved OS (38% vs. 24%, HR 0.69; 95% CI: 0.50-0.95, P=0.02) were achieved in the neoadjuvant group compared to the surgery alone group (40).

A trial from the European Organization for Research and Treatment of Cancer (EORTC 40954) did not support increased survival with neoadjuvant chemotherapy compared with surgery alone, although it was terminated early due to poor recruitment. In recruited patients, however, two 48-day cycles of neoadjuvant cisplatin, d-L-folinic acid, and fluorouracil did improve R0 resection (81.9% vs. 66.7%, P=0.036) and decreased lymph node metastasis rates (61.4% vs. 76.5%, P=0.018) compared with surgery alone (41).

**Neoadjuvant CRT in GC**

The efficacy of adjuvant CRT demonstrated in the Intergroup 0116 trial (25) and the advantages of a neoadjuvant approach in other aggressive malignancies have motivated application of neoadjuvant CRT in GC. Single arm studies demonstrating improvements in R0 resection rate and the achievement of pathological complete response (pCR) with preoperative CRT have been promising. In a phase I multi-institutional single-arm trial, Ajani et al. demonstrated R0 resection and pCR rates of 70% and 30%, respectively, with preoperative CRT consisting of two 28-day cycles of induction fluorouracil, leucovorin, and cisplatin followed by fluorouracil-based CRT to 45 Gy (42). Pathological complete response, pathologic partial response, R0 resection, and postoperative T/N stage were associated with improved OS (37). Another multi-institutional phase II trial of preoperative induction chemotherapy with two cycles of fluorouracil, leucovorin, and cisplatin followed by paclitaxel, fluorouracil, and concurrent 45 Gy radiotherapy demonstrated R0 resection rates of 77% and pCR rate of 26% (43). Similarly, in a recent Dutch phase I/II study, patients with locally advanced GC had an R0 resection rate of 72%, pCR rate of 16%, and near-complete response rate of 24% following neoadjuvant therapy with carboplatin and paclitaxel with concurrent radiotherapy (44). Other phase I and II trials of neoadjuvant CRT for GC in both Eastern and Western patients have been equally promising and are summarized in Table 1 (45-50).

Despite these promising results, phase III RCTs demonstrating a survival benefit and/or improved R0 resection rates following neoadjuvant CRT in distal GC are lacking. However, studies including patients with EGI cancers have recently been conducted. A 2009 German phase III RCT (POET study) evaluated the impact of adding CRT to neoadjuvant chemotherapy with cisplatin, fluorouracil, and leucovorin versus chemotherapy alone for tumors of the lower esophagus and gastric cardia (51). Although this study found a trend toward improved survival with the addition of preoperative CRT to chemotherapy alone (47.4% vs. 27.7% 3-year survival, P=0.07), it was inadequately powered and primarily included patients with esophageal cancer.

In the more recent Dutch CROSS trial, patients with potentially resectable esophageal or EGI cancer (3/4 adenocarcinomas, 1/4 SCC, majority distal esophageal, 11% EGI) were randomized to preoperative CRT using weekly paclitaxel 50 mg/m^2 plus carboplatin (AUC of 2) plus concurrent radiotherapy (41.4 Gy over 5 weeks) or surgery alone. Preoperative CRT was well tolerated, with grade 3 or worse hematologic toxicity in 7%, and grade 3 or higher non-hematologic toxicity in <13%; there were also no differences in postoperative morbidity or mortality between the two groups. The R0 resection rate was higher with CRT (92% vs. 69%), and 29% of those treated with CRT had pCR. At a median follow-up of 32 months, median OS was significantly better with preoperative CRT (HR for death 0.657, 95% CI: 0.495-0.871, P=0.003; 3-year survival rate: 58% vs. 44%) (35).

Based on these data and encouraging phase I-III evidence, well-designed and adequately powered phase III RCTs comparing neoadjuvant CRT versus chemotherapy alone in distal gastric tumors are warranted.
Patient selection for neoadjuvant therapy

While a neoadjuvant approach can be applied broadly, its advantages may be most pronounced in specific patient subsets. Gastric resection is associated with substantial morbidity, particularly in certain high-risk patients groups. Using the ACS-NSQIP database, we recently demonstrated that older age, preoperative weight loss, and concomitant splenectomy and/or pancreatectomy are associated with increased risk of morbidity following total gastrectomy for GC (29). Such morbidity may preclude timely initiation of adjuvant therapy. Using a large cohort from the National Cancer Data Base (NCDB), we directly explored factors predicting omission of adjuvant therapy following gastric resection. Advancing age, medical comorbidities, non-privately insured/uninsured status, proximal tumor location, and clinical T1/2 and N0 classification were associated with adjuvant therapy omission (30). It is plausible; therefore, that a neoadjuvant approach may increase the likelihood of multimodality treatment completion in select patient subsets at highest risk for either morbidity from gastrectomy and/or omission of adjuvant therapy. Ultimately, such factors must be weighed against the risk of attrition due to treatment-related toxicity following neoadjuvant therapy, in order to develop a personalized treatment plan that optimizes multimodality therapy delivery.

Limitations of clinical staging may also influence selection of a neoadjuvant approach. Endoscopic ultrasound (EUS), a mainstay of preoperative staging, provides a relatively crude estimate of T- and N-classifications (52-54). While there is significant heterogeneity in the accuracy of EUS in the literature, a recent meta-analysis found a pooled EUS accuracy for N stage of only 64% and T stage of 75%, with better accuracy for T3 and T4 tumors than T1 and T2 tumors (55). Such limitations may favor primary surgery in lower risk patients who can be salvaged with adjuvant CRT if pathologic stage renders them eligible for multimodality therapy. Conversely, more liberal use of neoadjuvant therapy may be appropriate in ambiguously staged patients at higher risk for omission of adjuvant therapy.

Acknowledging the limitations of preoperative staging by EUS and the factors associated with high risk of morbidity

Table 1 Summary of phase I and II trials investigating impact of neoadjuvant chemoradiotherapy for locally advanced gastric cancer

<table>
<thead>
<tr>
<th>Trial (References)</th>
<th>N</th>
<th>Schedule</th>
<th>Number proceeding to surgery [%]</th>
<th>Post-operative mortality [%]</th>
<th>Pathological complete response [%]</th>
<th>Pathological complete or partial response [%]</th>
<th>R0 resection [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ajani et al. [2006] (43)</td>
<td>43</td>
<td>5-FU, leucovorin, cisplatin, XRT</td>
<td>36/43 [84]</td>
<td>0</td>
<td>11/43 [26]</td>
<td>NR</td>
<td>27/43 [63]</td>
</tr>
<tr>
<td>Inoue et al. [2012] (48)</td>
<td>12</td>
<td>S-1, XRT</td>
<td>12/12 [100]</td>
<td>0</td>
<td>2/12 [17]</td>
<td>10/12 [83]</td>
<td>11/12 [92]</td>
</tr>
<tr>
<td>Lee et al. [2012] (49)</td>
<td>12</td>
<td>S-1, oxaliplatin, XRT</td>
<td>12/12 [100]</td>
<td>0</td>
<td>1/12 [8]</td>
<td>6/12 [50]</td>
<td>11/12 [92]</td>
</tr>
</tbody>
</table>

*, contained patients with both esophageal and gastric cancer. Outcomes other than mortality were reported individually; 5-FU, fluorouracil; XRT, radiotherapy; NR, not recorded.
from gastrectomy or adjuvant therapy omission, we propose an algorithm for the approach to adjuvant or neoadjuvant treatment of GC based on both clinical stage and baseline patient characteristics (Figure 1). In this algorithm, all patients with a diagnosis of GC are formally staged with a combination of cross sectional imaging, EUS, and diagnostic laparoscopy. Patients with clinical T1-2, N0 and distal tumors proceed to surgery, while those with T3-4 tumors, evidence of regional LN metastases, or T2 proximal tumors receive neoadjuvant chemotherapy or CRT followed by surgery. Exceptions are made on an individual basis using nuanced clinical judgment. Given the implications of inadequate LN staging on long-term outcomes, patients should undergo sound oncologic operations with examination of at least 15 LNs (24); in our practice this is achieved by pancreas and spleen-preserving D2 gastrectomy (56). When surgery is the initial treatment modality, adjuvant treatment is selected on the basis of pathological stage at resection (i.e., IB-III based on intergroup criteria).

**Trials in progress**

Several ongoing studies have been designed to further characterize the optimal sequencing of multimodality therapy in GC. As would be expected from current regional variations in treatment of locally advanced GC, these sequencing combinations and schedules are quite heterogeneous and merit discussion.

The ongoing Dutch CRITICS trial compares preoperative chemotherapy alone with epirubicin, cisplatin, and capecitabine (ECX) followed by surgery and postoperative ECX alone versus preoperative ECX followed by surgery and postoperative CRT (NCT00407186) (57). TOPGEAR is an Australasian, Canadian, and European study evaluating preoperative ECF chemotherapy alone versus preoperative ECF plus CRT (NCT01924819). The UK-based MAGIC-B/MRC-ST03 trial compares perioperative ECX with or without bevacizumab for localized GC (NCT00450203).

In Asia, the PRODIGY trial is evaluating preoperative docetaxel, oxaliplatin, and S-1 followed by surgery and adjuvant S-1 versus surgery followed by S-1 alone (NCT01515748). The ARTIST II trial is a follow-up to the previously discussed ARTIST trial, further dissecting survival differences between CRT and chemotherapy alone in patients with LN-positive disease. In ARTIST II, patients...
with positive LNs found at the time of D2 gastrectomy will receive adjuvant S-1, adjuvant S-1 plus oxaliplatin, or adjuvant S-1, oxaliplatin, and CRT (NCT01761461).

Future directions

While biomarker-targeted therapy has received enormous attention in recent years, its potential remains largely untapped in GC. Indeed, a recent novel molecular classification of GC from the Cancer Genome Atlas may revolutionize targeted treatment paradigms in this disease (58). Consequently, future efforts will likely require the addition of targeted and biologic therapy to standard surgery, chemotherapy, and radiotherapy in GC in order to optimize long-term outcomes. While a comprehensive discussion of these agents is beyond the scope of this review, a few existing therapies deserve discussion.

Trastuzumab is a humanized monoclonal antibody that inhibits the HER2/neu receptor. In pivotal RCTs in both the adjuvant and neoadjuvant settings, trastuzumab has been shown to be effective in treating HER2-positive breast cancer; in GC, the role of trastuzumab in improving survival has only been elucidated in patients with advanced, non-operable HER2-positive GC (59). As is the case in breast cancer, HER2-positivity has been characterized as a negative prognostic factor for survival in GC. However, in a prospective observational study, HER2-positive advanced GC patients treated with trastuzumab and chemotherapy demonstrated comparable survival to HER2-negative patients treated with chemotherapy alone (60).

Other targeted therapies have been examined in advanced GC patients with encouraging results. Bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor, has been used as a chemotherapy adjunct in other GI malignancies including colon and rectal cancer (61-63). In the aforementioned AVAGAST trial, the addition of bevacizumab to cisplatin and capecitabine or fluorouracil in advanced GC patients improved progression-free survival and overall response rates, although it did not significantly impact OS (23). A prospective evaluation of biomarkers that might predict response to bevacizumab was incorporated in the trial design; interestingly, patients with baseline high VEGF-A and low neuropilin-1 levels displayed a trend toward improved survival with bevacizumab, suggesting that the optimal effect from bevacizumab may be realized in appropriately selected patients (64). The addition of bevacizumab to perioperative ECX demonstrated acceptable toxicity in a phase II trial (65).

Ramucirumab is a VEGF receptor-2 antagonist that has been demonstrated to improve survival in advanced GC, either as a single agent or in combination with taxane-based chemotherapy, with an additive advantage in response rate outcomes (66,67).

While utilization of such approaches in a salvage setting for metastatic disease are supported by strong rationale and some evidence, benefit of targeted agents for resectable disease has been less extensively explored. Treatment related toxicity will emerge as a critical determinant of the applicability of such regimens in the non-metastatic disease population.

Conclusions

Benefits of a neoadjuvant approach have been demonstrated in the management of gastrointestinal malignancies. Neoadjuvant therapy is probably underutilized in the management of GC. The morbidity associated with gastric resection precludes timely adjuvant therapy in a subset of patients and multimodality therapy has proven efficacy. Neoadjuvant therapy allows for an assessment of response to therapy, may improve treatment compliance and can inform selection of patients for surgical resection. Future studies are warranted and may establish a role for more effective and better tolerated neoadjuvant regimens.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References


